241
Participants
Start Date
September 30, 2015
Primary Completion Date
April 30, 2020
Study Completion Date
April 30, 2020
SD-101(1)
SD-101 administered intratumorally at escalating doses (up to 11 doses).
Pembrolizumab
Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).
SD-101(2)
Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).
Pembrolizumab
Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
SD-101(3)
Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).
Pembrolizumab
Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
Auckland City Hospital, Auckland
Melanoma Institute, Wollstonecraft
Liverpool Hospital, Westmead
The Tweed Hospital, Tweed Heads
Waikato Hospital, Hamilton
Christchurch Hospital, Christchurch
Adelaide Cancer Centre - Ashford Cancer Centre, Kurralta Park
Roswell Park Cancer Institute, Buffalo
Penn State Hershey Medical Center, Hershey
Inova Schar Cancer Institute, Fairfax
West Virginia University, Morgantown
Duke University Medical Center, Durham
Levine Cancer Institute, Charlotte
Medical University of South Carolina, Charleston
Georgia Cancer Center - Northside Hospital Central Research Department, Atlanta
Mount Sinai Comprehensive Cancer Center, Miami Beach
University of Alabama School of Medicine, Birmingham
University of Alabama, Birmingham
University Hospitals Cleveland Medical Center - Seidman Cancer center, Cleveland
The Christ Hospital, Cincinnati
University of Michigan, Ann Arbor
Barbara Ann Karmanos Cancer Institute, Detroit
University of Iowa Healthcare, Iowa City
University of Minnesota Masonic Cancer Center, Minneapolis
Northwestern University, Chicago
Nebraska Methodist Hospital, Omaha
University of Oklahoma Health Sciences Center, Oklahoma City
Mary Crowley Cancer Research Center, Dallas
University of Colorado, Aurora
University of Utah Health Care - Huntsman Cancer institute, Salt Lake City
University of Arizona Cancer Center, Tucson
University of California, Los Angeles, Los Angeles
University of California, San Diego, San Diego
University of California San Francisco, San Francisco
Stanford Hospitals and Clinics, Palo Alto
Providence Portland Medical Center, Portland
Atlantic Health, Morristown
Hollywood Private Hospital / Affinity Research, Nedlands
Charité - Universitätsmedizin Berlin, Berlin
Klinikum BuxtehudeDermato-Onkologie Studienzentrale, Buxtehude
Uniklinikum Dresden Klinik und Poliklinik für Dermatologie, Dresden
Universitätshautklinik Frankfurt, Frankfurt
Medizinische Hochschule Hannover, Hanover
HNO-Universitätsklinik Jena, Jena
Universitätshautklinik Magdeburg, Magdeburg
Universitätsklinikum Regensburg, Regensburg
Universitätsklinikum Tübingen, Tübingen
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Dynavax Technologies Corporation
INDUSTRY